Phasiq, an Ann Arbor proteomics startup, just received a pre-seed round of funding from the student-run Zell Lurie commercialization fund at the University of Michigan, it said a statement.
Phasiq is developing a multiplex assay that’s meant to quickly and inexpensively identify several proteins in a sample. It could be used in multiple disease diagnostics and for drug development. The funding will be used to automate its manufacturing process to make production scalable for its assay.
The company, founded in 2012, plans to launch its assay commercially next year. Read about how its multiplexing technology works here.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The underlying research comes from University of Michigan professor Shuichi Takayama, who works in the field of macromolecular science and biomedical engineering.